Mechanisms that elevate either circulating FGF21 or adiponectin have been shown to increase energy expenditure, reduce adiposity, decrease insulin resistance and hyperglycaemia, and are associated with reduced cardiovascular disease events (31). This evidence concerns the gene FGF21 and cardiovascular disorder.